Photo from Roche Diagnostics Asia Pacific/LinkedIn
Jul 18, 2024, 08:37
Advancing Patient Access to NGS for cancer in APAC
Roche Diagnostics Asia Pacific posted on LinkedIn:
“Did you know that clinical outcomes for cancer in APAC have an estimated mortality-to-incidence ratio (MIR) of 0.52 as compared to 0.32 in the West?
This is why innovative technologies like Next-Generation Sequencing (NGS) are a potential game-changer in cancer care. This latest paper written by Asia Pacific Medical Technology Association (APACMed), explores NGS’s role in personalized treatment, its real-world impact on patient outcomes, and a value assessment framework to improve access. .
Read about this in the whitepaper here.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08